HRAS and hereditary pheochromocytoma-paraganglioma: The earliest data regarding the state of Ras signaling pathway hyperactivation in pheochromocytoma pathogenesis were contradictory [218–220] However, an analysis of 169 endocrine tumor samples in 1992 revealed the first H-Ras mutation in pheochromocytoma [221].